ArticleNature biomedical engineering2026
Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery.
Abstract read
In one paragraph
Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Novel immunotherapies for prostate cancer.Urologic oncology · 2026Review
- Advancing In Vivo Chimeric Antigen Receptor T-Cell Engineering to Accelerate Clinical Translation.MedComm · 2026Review
- Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases.Stem cell research & therapy · 2026Review
- Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma.Cancer research · 2026Article
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment.Journal of hematology & oncology · 2026Article
- Focal radiotherapy improves CAR T cell therapy targeting prostate cancer.bioRxiv : the preprint server for biology · 2026Article
- Cellular immunotherapy in melanoma: the next frontier in cancer treatment.Journal of experimental & clinical cancer research : CR · 2026Review
- Engineering human PEG10-based nanoparticles for RNA self-packaging, delivery and cancer therapy.Nature communications · 2026Article
- The genome takes the wheel: CAR T with built-in circuits.Immuno-oncology technology · 2026Article
- Advanced 3D cancer models for analyzing tumor-immune cell interaction and therapeutic response.Molecular cancer · 2026Review
- A Comprehensive Evaluation of CAR-T Cell Gene Therapy, Tracing its Revolutionary Clinical Breakthroughs and Advancements Towards Next-Generation Engineering.Expert reviews in molecular medicine · 2026Review
- In Vivo T-Cell Engineering: Revolution in Delivery Strategies and Clinical Translation.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Immunotherapy for pediatric solid tumors: overcoming biological barriers through rational multimodal combinations.Cancer immunology, immunotherapy : CII · 2026Review
- Immuno-cytotoxic convergence: integrating antibody‒drug conjugates and immunofusion proteins to overcome resistance in gastrointestinal cancers.Journal of hematology & oncology · 2026Review
- Integrating CAR-T therapy with PD-1/PD-L1 blockade: Mechanisms, synergy, and optimized strategies in NSCLC.iScience · 2026Review
- CAR-macrophages: a new chapter in cancer immunotherapy.Acta biochimica et biophysica Sinica · 2026Article
- Targeting urological cancers with CAR-T cell therapy: current landscape and future directions.Journal of translational medicine · 2026Review
- Research progress on immune tolerance mechanisms in liver metastatic tumors and the "Liver-metastasis-oriented shared-mechanism therapeutic strategy" approach.Medical review (2021) · 2026Review
- CAR-T therapy in non-small cell lung cancer: Clinical prospects, potential, and strategies for cardiotoxicity management.Translational oncology · 2026Article
Corrections and comments
- Update of
Authors and funding
20 authors.
John P MuradKeck School of Medicine (KSOM)/Norris Center for Cancer Cellular Immunotherapy Research (CCCIR), Division of Medical Oncology, Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-0637-2414
Lea ChristianDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
Reginaldo RosaKeck School of Medicine (KSOM)/Norris Center for Cancer Cellular Immunotherapy Research (CCCIR), Division of Medical Oncology, Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-0984-8959
Yuwei RenKeck School of Medicine (KSOM)/Norris Center for Cancer Cellular Immunotherapy Research (CCCIR), Division of Medical Oncology, Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA.
Alyssa J BuckleyKeck School of Medicine (KSOM)/Norris Center for Cancer Cellular Immunotherapy Research (CCCIR), Division of Medical Oncology, Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA.
Eric Hee Jun LeeWallace H. Coulter Department of Biomedical Engineering, Georgia Tech College of Engineering and Emory School of Medicine, Atlanta, GA, USA.
Lupita S LopezKeck School of Medicine (KSOM)/Norris Center for Cancer Cellular Immunotherapy Research (CCCIR), Division of Medical Oncology, Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA.
Anthony K ParkDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
Jason YangDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-7156-5872
Yukiko YamaguchiKeck School of Medicine (KSOM)/Norris Center for Cancer Cellular Immunotherapy Research (CCCIR), Division of Medical Oncology, Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA.
Candi TracDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
Lauren N AdkinsKeck School of Medicine (KSOM)/Norris Center for Cancer Cellular Immunotherapy Research (CCCIR), Division of Medical Oncology, Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA.
Wen-Chung ChangDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-1982-0725
Catalina MartinezKeck School of Medicine (KSOM)/Norris Center for Cancer Cellular Immunotherapy Research (CCCIR), Division of Medical Oncology, Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA.
Carl H JuneCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-0241-3557
Stephen J FormanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
Jun IshiharaDepartment of Bioengineering, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-9083-9859
John K LeeDivision of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-6570-2180
Lawrence A SternDepartment of Chemical, Biological, and Materials Engineering, University of South Florida, Tampa, FL, USA.
Saul J PricemanKeck School of Medicine (KSOM)/Norris Center for Cancer Cellular Immunotherapy Research (CCCIR), Division of Medical Oncology, Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA. priceman@usc.edu.ORCID http://orcid.org/0000-0002-8136-2112
Funding
Prostate Cancer Foundation (PCF) PCF TACTICAL AWARD
Abstract
Chimeric antigen receptor (CAR)-T cell efficacy in solid tumours is limited due in part to the immunosuppressive tumour microenvironment (TME). To improve antitumour responses, we hypothesized that enabling CAR-T cells to secrete bifunctional fusion proteins consisting of a cytokine modifier such as TGFβ
Indexed as
B7-H1 AntigenImmunotherapy, AdoptiveInterleukin-12NeoplasmsReceptors, Chimeric AntigenRecombinant Fusion ProteinsT-LymphocytesAnimalsCell Line, TumorFemaleHumansInterleukin-15MaleMiceOvarian NeoplasmsProstatic NeoplasmsB7-H1 AntigenCD274 protein, humanInterleukin-12Interleukin-15Receptors, Chimeric AntigenRecombinant Fusion Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.